Wet Age-Related Macular Degeneration Pipeline 2024

DelveInsight's, "Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Insight, 2024," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report
• DelveInsight's Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.
• The leading companies working in the Wet Age-Related Macular Degeneration market include Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.
• Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
• October 2023: Neuracle Genetics Inc. announced a study of Phase 1 clinical trials for NG101 AAV gene therapy. This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD). This is a Phase 1/2a, multicenter, open-label, dose escalation study to evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy, administered by subretinal injection in patients with active wAMD symptoms. The study will be conducted at approximately 6 sites in Canada and the USA.
• October 2023: Sam Chun Dang Pharm Co. Ltd announced a study of Phase 3 clinical trials for SCD411 and Aflibercept. Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.

Request a sample and discover the recent advances in Wet Age-Related Macular Degeneration Treatment Drugs @ Wet Age-Related Macular Degeneration Pipeline Outlook Report- https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Wet Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Wet Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Wet Age-Related Macular Degeneration clinical trial landscape.

Wet Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative).

Find out more about Wet Age-Related Macular Degeneration Treatment Drugs @ Drugs for Wet Age-Related Macular Degeneration Treatment- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wet Age-Related Macular Degeneration Emerging Drugs Profile
• Abicipar pegol: Molecular Partners
• SOK583A1: Sandoz
• BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.
• ADVM-022: Adverum Biotechnologies

Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment
The Wet Age-Related Macular Degeneration pipeline report proffers an integral view of the Wet Age-Related Macular Degeneration emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

DelveInsight's Wet Age-Related Macular Degeneration Pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Wet Age-Related Macular Degeneration Pipeline Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Wet Age-Related Macular Degeneration Pipeline Therapies @ Wet Age-Related Macular Degeneration Clinical Trials Assessment- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Wet Age-Related Macular Degeneration Pipeline Report
• Coverage- Global
• Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Wet Age-Related Macular Degeneration Companies- Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.
• Wet Age-Related Macular Degeneration Pipeline Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.

Dive deep into rich insights for new drugs for Wet Age-Related Macular Degeneration Treatment, Visit @ Wet Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Wet Age-related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wet Age-related Macular Degeneration- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Abicipar pegol: Molecular Partners
9. Late Stage Products (Phase III)
10. SOK583A1: Sandoz
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. ADVM-022: Adverum Biotechnologies
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Wet Age-related Macular Degeneration- Unmet Needs
23. Wet Age-related Macular Degeneration- Market Drivers and Barriers
24. Appendix

For further information on the Wet Age-Related Macular Degeneration Pipeline therapeutics, reach out to Wet Age-Related Macular Degeneration Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

This release was published on openPR.